'Humiliation': French see Covid-19 vaccine flops as sign of decline
France's slip from frontrunner to laggard in the race to develop a Covid-19 vaccine has sparked dismay among politicians, reigniting a debate about the country's scientific prowess and its global standing.
France, the land of vaccine pioneer Louis Pasteur, has a long and celebrated history when it comes to medical breakthroughs.
With the world-renowned research centre that bears his name in Paris, the Pasteur Institute, as well as leading pharma group Sanofi, the country looked well positioned in the race to produce a jab against the novel coronavirus.
But the Pasteur Institute announced Monday that it was abandoning research on its most promising prospect, while Sanofi – an early frontunner in the vaccine race – has said its candidate for inoculation will not be ready before the end of 2021 at best.
"It's a sign of the decline of the country and this decline is unacceptable," François Bayrou, a close political ally of President Emmanuel Macron, said Tuesday.
Bayrou, head of the centrist MoDem party and named by Macron last year as commissioner for long-term government planning, said the problem was a brain-drain from France to the United States.
Speaking on France Inter radio, he said it was "not acceptable that our best researchers, the most brilliant of our researchers, are sucked up by the American system".
He referred to Stéphane Bancel, a Frenchman who heads US-based biotech firm Moderna, whose vaccine was the second to be approved for use in the United States and Europe.
Experts say the US government has invested more in vaccine research in the previous decades, while innovative companies are also drawn to the country because raising funds from private investors is easier and quicker.
Long-time Socialist minister Ségolène Royal, on the other hand, blamed "liberal ideology" for reductions in public funding for vaccine research, while Communist Party head Fabien Roussel called the setbacks a "humiliation".
Standing up to les anglo-saxons
The failure of French Covid vaccine research so far touches on several sensitive issues for the country.
The political class and many voters have long worried about France's relative decline in power and influence – the ominous "déclassement" – in an increasingly globalised world.
This tendency is seen by many analysts as part of the explanation for strong support for the far-right party of Marine Le Pen, whose rhetoric is tinged with nostalgia for the past.
Since World War II, French governments have always had a strong industrial policy which has seen the promotion and protection of national champions to rival "les anglo-saxons" in Britain and America.
Sanofi, the only remaining major French pharma group, has come in for fierce public criticism, particularly in May last year when CEO Paul Hudson – a British citizen – said the United States would get first access to a future vaccine because it invested more in research.
His words kicked up a storm in France, and the company's managers were duly summoned by President Macron and his ministers.
Sanofi followed up this public relations disaster at home by announcing 1,700 job cuts a month later, including 1,000 in France.
The vaccine flops come at the height of a pandemic that has rattled the self-confidence of many of the world's richest nations, exposing a lack of preparedness and huge gaps in their manufacturing capabilities.
Amid the self-criticism and introspection, some experts and politicians have called on France to avoid taking the vaccine setbacks too hard.
Chance plays a major role in cutting-edge research, evident in the work of the most celebrated past French researchers from Pasteur to Nobel Prize-winning chemist Marie Curie.
Nathalie Coutinet, an economics of medicine researcher at the Sorbonne University in Paris, said many different approaches were being taken by scientists worldwide in the Covid fight.
The Pasteur Institute bet on adapting a measles vaccine to fight Covid, while Sanofi tried to tweak one of its flu jabs – only for a lab mistake to throw it off track.
The most successful approach among Western researchers turned out to be "messenger RNA," which was harnessed by German biotech group BioNTech as well as Moderna, whose jabs have been approved.
"If everyone had opted for RNS Messenger and it hadn't worked, we would have said it was stupid," Coutinet told AFP.
(FRANCE 24 with AFP)
Daily newsletterReceive essential international news every morningSubscribe